PT-141 10mg
Central Melanocortin Agonist for Sexual Function Research
PT-141 (bremelanotide) is an MC4R agonist studied for female hypoactive sexual desire disorder and male erectile dysfunction, working centrally through brain pathways rather than the vascular system. FDA-approved as Vyleesi for HSDD.
Central Melanocortin Agonist for Sexual Function Research
PT-141 is a cyclic melanocortin peptide derived from Melanotan II, retaining potent MC3R and MC4R agonism while minimizing MC1R pigmentation effects. It activates dopaminergic and noradrenergic pathways in the hypothalamus associated with sexual arousal.
As one of the most studied compounds in the skin & anti-aging research space, PT-141 has attracted sustained scientific interest across Sexual function research, HSDD studies, Melanocortin system research. Peer-reviewed evidence indicates that fDA-approved analogue for female HSDD, which has positioned PT-141 as a reference standard for researchers exploring sexual function research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
PT-141 Documented Benefits: 3 Documented Mechanisms
Central Sexual Arousal
Activates MC4R in the hypothalamus to increase dopamine and noradrenaline release associated with sexual motivation.
FDA-Approved Mechanism
Same active compound as Vyleesi (bremelanotide), approved for HSDD in premenopausal women.
Non-Vascular Pathway
Works through CNS pathways, not PDE5 inhibition, making it complementary to other sexual function research.
How PT-141 Works: Molecular Mechanism & Pathway
Cyclic MC3R/MC4R agonist activating hypothalamic dopaminergic pathways to enhance sexual arousal via central nervous system signaling.
The 3 primary research pathways identified for PT-141 — Central Sexual Arousal, FDA-Approved Mechanism, Non-Vascular Pathway — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that clinically studied for male erectile dysfunction, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, PT-141's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
PT-141 is routinely studied alongside GHK-Cu and Melanotan I in skin & anti-aging-focused compound panels. Researchers investigating sexual function research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that cNS pathway distinct from PDE5 inhibitors has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All PT-141 research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- FDA-approved analogue for female HSDD
- Clinically studied for male erectile dysfunction
- CNS pathway distinct from PDE5 inhibitors
Ideal For
- Sexual function research
- HSDD studies
- Melanocortin system research
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on PT-141. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
FDA-approved analogue for female HSDD
Clinically studied for male erectile dysfunction
CNS pathway distinct from PDE5 inhibitors
Third-Party Verified Every Batch
Each vial of PT-141 is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
